Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 21'st Apr 2026
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
08:00am, Friday, 17'th Apr 2026
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
07:00am, Tuesday, 14'th Apr 2026
ALACHUA, Fla. and TAMPA, Fla.
SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN
04:45am, Sunday, 05'th Apr 2026
SG Americas Securities LLC boosted its position in AxoGen, Inc. (NASDAQ: AXGN) by 459.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6
AxoGen, Inc. $AXGN Shares Sold by JPMorgan Chase & Co.
04:57am, Saturday, 04'th Apr 2026
JPMorgan Chase and Co. cut its holdings in shares of AxoGen, Inc. (NASDAQ: AXGN) by 44.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fun
Exchange Traded Concepts LLC Sells 26,743 Shares of AxoGen, Inc. $AXGN
03:52am, Saturday, 04'th Apr 2026
Exchange Traded Concepts LLC lowered its stake in AxoGen, Inc. (NASDAQ: AXGN) by 45.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exc
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
02:59pm, Tuesday, 24'th Mar 2026
An Axogen executie reported selling 5,221 shares of Common Stock for a transaction value of approximately $171,000 on March 16, 2026. This represented 1.95% of total holdings as reported in the Form 4
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
07:53pm, Saturday, 21'st Mar 2026
DAFNA Capital Management sold 265,456 AXGN shares in the fourth quarter, with an estimated transaction value of $6.53 million based on quarterly average prices. Meanwhile, the quarter-end position val
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN
03:52am, Sunday, 15'th Mar 2026
ArrowMark Colorado Holdings LLC grew its stake in AxoGen, Inc. (NASDAQ: AXGN) by 20.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Com
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
01:14am, Saturday, 14'th Mar 2026
AxoGen (NASDAQ: AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company's ability to serve patients across a broad range of peripheral nerve repair
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
04:48am, Saturday, 07'th Mar 2026
AxoGen (NASDAQ: AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected stan
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
11:15am, Friday, 06'th Mar 2026
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Axogen Q4: EPS Miss Amid Biologics Transition
05:23am, Wednesday, 25'th Feb 2026
Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biol
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
11:37am, Tuesday, 24'th Feb 2026
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
AxoGen (AXGN) Q4 Earnings Miss Estimates
10:41am, Tuesday, 24'th Feb 2026
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago.
